Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Muamycin
Ovarian Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Muamycin
Uterine Corpus Cancer
City of Hope Medical Center
P1
CC
(43)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
P1
CC
(43)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
P1
CC
(43)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
High Grade B-Cell Lymphoma
City of Hope Medical Center
P1
CC
(43)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Mantle Cell Lymphoma
City of Hope Medical Center
P1
CC
(43)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Myelodysplastic/Myeloproliferative Neoplasm
City of Hope Medical Center
P1
CC
(43)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
P1
CC
(43)
Muzastotug
Colorectal Carcinoma
City of Hope Medical Center
P1
CC
(43)
Mvf-Her-2 (266-296)
Gastric Cancer
Pravin T.P Kaumaya
P1
CC
(43)
Myrciaria Dubia Prebiotic Supplement
Renal Cell Carcinoma
City of Hope Medical Center
P1
CC
(43)
Mytx-011
Non-Small Cell Squamous Lung Carcinoma
Mythic Therapeutics
P1
CC
(43)
N-(2-chloro-3-((3,4-dihydro-2H-pyrimido[1,2-c] quinazolin-10- yl)oxy) phenyl)propane-1-sulfonamide hydrochloride
Cancer
ABM Therapeutics Shanghai Company Limited
P1
CC
(43)
n803
Non-Hodgkin Lymphoma
ImmunityBio, Inc.
P1
CC
(43)
Nadravaleucel
Breast Neoplasm
Vall d'Hebron Institute of Oncology
P1
CC
(43)
Nadravaleucel
Hematopoietic And Lymphoid Cell Neoplasm
David Wald
P1
CC
(43)
Nadravaleucel
Rectal Cancer
David Wald
P1
CC
(43)
Nadravaleucel
Glioblastoma
M.D. Anderson Cancer Center
P1
CC
(43)
Naptumomab Estafenatox
Cervical Squamous Cell Carcinoma
NeoTX Therapeutics Ltd.
P1
CC
(43)
Naptumomab Estafenatox
Estrogen-Receptor Positive Breast Cancer
NeoTX Therapeutics Ltd.
P1
CC
(43)
Naptumomab Estafenatox
Her2-Receptor Negative Breast Cancer
NeoTX Therapeutics Ltd.
P1
CC
(43)
Naptumomab Estafenatox
Pancreatic Adenocarcinoma
NeoTX Therapeutics Ltd.
P1
CC
(43)
Naptumomab Estafenatox
Triple-Negative Breast Carcinoma
NeoTX Therapeutics Ltd.
P1
CC
(43)
Navitoclax
Acute Myeloid Leukemia
Medical College of Wisconsin
P1
CC
(43)
Navitoclax
Ovarian Serous Adenocarcinoma
Sunnybrook Health Sciences Centre
P1
CC
(43)
Showing 3426 to 3450 of 9,920 assets
Previous
Page 138 of 397
Next
